Biomarkers Predicting Alzheimer's Disease in Cognitively Normal Aging

被引：31
作者：
Shim, Yong S. [1 ,3 ]
Morris, John C. [1 ,2 ]
机构：
[1] Washington Univ Sch Med, Knight Alzheimers Dis Res Ctr, St Louis, MO 63108 USA
[2] Washington Univ Sch Med, Dept Neurol, St Louis, MO 63108 USA
[3] Catholic Univ Korea Coll Med, Bucheon St Marys Hosp, Dept Neurol, Puchon, South Korea
来源：
JOURNAL OF CLINICAL NEUROLOGY | 2011年 / 7卷 / 02期
关键词：
Alzheimer's disease; preclinical; biomarker; CEREBROSPINAL-FLUID TAU; PITTSBURGH COMPOUND-B; AMYLOID-BETA-PROTEIN; FOLLOW-UP; DIFFERENTIAL-DIAGNOSIS; ENTORHINAL CORTEX; BRAIN ATROPHY; NEURON NUMBER; CSF LEVELS; IMPAIRMENT;
D O I：
10.3988/jcn.2011.7.2.60
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The pathophysiologic process of Alzheimer's disease (AD) begins years before the diagnosis of clinical dementia. This concept of preclinical AD has arisen from the observation of AD pathologic findings such as senile plaques and neurofibrillary tangles in the brains of people who at the time of death had normal cognitive function. Recent advances in biomarker studies now provide the ability to detect the pathologic changes of AD, which are antecedent to symptoms of the illness, in cognitively normal individuals. Functional and structural brain alterations that begin with amyloid-beta accumulation already show the patterns of abnormality seen in individuals with dementia due to AD. The presence of preclinical AD provides a critical opportunity for potential interventions with disease-modifying therapy. This review focuses on the studies of antecedent biomarkers for preclinical AD. J Clin Neurol 2011;7:60-68
引用
收藏
页码：60 / 68
页数：9
相关论文
共 82 条
[1]   Fluctuations of CSF amyloid-β levels -: Implications for a diagnostic and therapeutic biomarker [J].
Bateman, Randall J. ;
Wen, Guolin ;
Morris, John C. ;
Holtzman, David M. .
NEUROLOGY, 2007, 68 (09) :666-669
[2]   CSF markers for incipient Alzheimer's disease [J].
Blennow, K ;
Hampel, H .
LANCET NEUROLOGY, 2003, 2 (10) :605-613
[3]   CSF total tau, aβ42 and phosphorylated tau protein as biomarkers for Alzheimer's disease [J].
Blennow, K ;
Vanmechelen, E ;
Hampel, H .
MOLECULAR NEUROBIOLOGY, 2001, 24 (1-3) :87-97
[4]  
Bobinski M, 2000, NEUROSCIENCE, V95, P721
[5]  
Bosscher L, 2001, MRI TEMPORAL LOBE EV
[6]   NEUROPATHOLOGICAL STAGING OF ALZHEIMER-RELATED CHANGES [J].
BRAAK, H ;
BRAAK, E .
ACTA NEUROPATHOLOGICA, 1991, 82 (04) :239-259
[7]   Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 [J].
Buerger, K ;
Zinkowski, R ;
Teipel, SJ ;
Tapiola, T ;
Arai, H ;
Blennow, K ;
Andreasen, N ;
Hofmann-Kiefer, K ;
DeBernardis, J ;
Kerkman, D ;
McCulloch, C ;
Kohnken, R ;
Padberg, F ;
Pirttilä, T ;
Schapiro, MB ;
Rapoport, SI ;
Möller, HJ ;
Davies, P ;
Hampel, H .
ARCHIVES OF NEUROLOGY, 2002, 59 (08) :1267-1272
[8]   Absence of Pittsburgh Compound B Detection of Cerebral Amyloid β in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease [J].
Cairns, Nigel J. ;
Ikonomovic, Milos D. ;
Benzinger, Tammie ;
Storandt, Martha ;
Fagan, Anne M. ;
Shah, Aarti R. ;
Reinwald, Lisa Taylor ;
Carter, Deborah ;
Felton, Angela ;
Holtzman, David M. ;
Mintun, Mark A. ;
Klunk, William E. ;
Morris, John C. .
ARCHIVES OF NEUROLOGY, 2009, 66 (12) :1557-1562
[9]   Trajectories of brain loss in aging and the development of cognitive impairment [J].
Carlson, N. E. ;
Moore, M. M. ;
Dame, A. ;
Howieson, D. ;
Silbert, L. C. ;
Quinn, J. F. ;
Kaye, J. A. .
NEUROLOGY, 2008, 70 (11) :828-833
[10]   Preclinical Properties of 18F-AV-45: A PET Agent for Aβ Plaques in the Brain [J].
Choi, Seok Rye ;
Golding, Geoff ;
Zhuang, Zhiping ;
Zhang, Wei ;
Lim, Nathaniel ;
Hefti, Franz ;
Benedum, Tyler E. ;
Kilbourn, Michael R. ;
Skovronsky, Daniel ;
Kung, Hank F. .
JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (11) :1887-1894
123456789